Profile data is unavailable for this security.
About the company
Zhejiang Huahai Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, manufacture and sales of generic drugs, biological drugs, innovative drugs and specialty active pharmaceutical ingredients (APIs) in multiple dosage forms. The Company's pharmaceutical preparations and APIs cover cardiovascular, mental disorder, nervous system and anti-infection fields. The Company's products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, oseltamivir phosphate capsules, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, febuxostat tablets and torsemide injection. The Company also provides technical services and pharmaceutical import and export trade business.
- Revenue in CNY (TTM)9.35bn
- Net income in CNY1.14bn
- Incorporated2001
- Employees8.22k
- LocationZhejiang Huahai Pharmaceutical Co LtdXunqiao, Linhai CityTAIZHOU 317024ChinaCHN
- Phone+86 57 685991096
- Fax+86 57 685016010
- Websitehttps://www.huahaipharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Resources Dubl-Crne Phrmctl Co Ltd | 11.22bn | 1.65bn | 22.95bn | 12.27k | 13.74 | 2.25 | -- | 2.04 | 1.61 | 1.61 | 10.93 | 9.81 | 0.7106 | 3.04 | 6.08 | 914,865.00 | 10.54 | 8.40 | 14.70 | 11.08 | 56.34 | 58.19 | 14.83 | 11.98 | 1.26 | -- | 0.0633 | 35.91 | 6.20 | 4.44 | 12.96 | 6.60 | 21.46 | -1.63 |
| Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 3.88bn | -422.97m | 23.15bn | 1.45k | -- | 3.69 | -- | 5.97 | -0.3269 | -0.3269 | 2.43 | 3.88 | 0.3774 | 0.5012 | 4.35 | 2,672,280.00 | -4.12 | 8.97 | -5.76 | 13.15 | 41.00 | 45.59 | -10.91 | 20.12 | 1.51 | -2.96 | 0.269 | 26.33 | 5.89 | 18.25 | -117.37 | -- | 38.32 | 13.75 |
| Shanghai Junshi Biosciences Co Ltd | 1.79bn | -1.80bn | 26.02bn | 2.53k | -- | 4.87 | -- | 14.56 | -1.83 | -1.83 | 1.81 | 6.26 | 0.1593 | 0.8406 | 4.29 | 695,986.10 | -17.55 | -18.87 | -21.98 | -23.11 | 69.07 | 69.13 | -110.18 | -88.41 | 1.75 | -67.73 | 0.3065 | -- | 3.38 | 248.39 | 4.38 | -- | 8.36 | -- |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 9.35bn | 1.14bn | 27.11bn | 8.22k | 23.78 | 3.08 | -- | 2.90 | 0.7772 | 0.7772 | 6.34 | 5.99 | 0.4922 | 1.02 | 3.51 | 1,137,186.00 | 6.01 | 5.67 | 8.37 | 8.07 | 61.97 | 60.52 | 12.21 | 11.61 | 0.7919 | 6.25 | 0.4541 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
| Hubei Jumpcan Pharmaceutical Co Ltd | 8.92bn | 2.78bn | 27.54bn | 5.23k | 9.86 | 1.96 | -- | 3.09 | 3.03 | 3.03 | 9.71 | 15.27 | 0.5135 | 3.08 | 4.60 | 1,706,101.00 | 16.04 | 16.23 | 20.68 | 20.88 | 78.36 | 82.64 | 31.23 | 24.42 | 3.55 | -- | 0.1024 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
| Gan & Lee Pharmaceuticals | 2.95bn | 580.86m | 28.03bn | 4.48k | 47.72 | 2.50 | -- | 9.51 | 0.9773 | 0.9773 | 4.97 | 18.65 | 0.2558 | 0.8458 | 8.94 | 657,602.00 | 5.04 | 8.30 | 5.40 | 8.83 | 72.92 | 85.39 | 19.71 | 26.44 | 6.77 | -- | 0.0005 | 13.65 | 52.31 | 1.78 | 177.37 | -18.30 | 1.50 | -- |
| Xiamen Amoytop Biotech Co Ltd | 2.60bn | 740.69m | 30.02bn | 1.96k | 40.53 | 13.26 | -- | 11.57 | 1.82 | 1.82 | 6.38 | 5.57 | 1.08 | 0.8928 | 6.18 | 1,324,099.00 | 30.73 | 17.96 | 35.90 | 21.02 | 92.71 | 90.48 | 28.54 | 19.17 | 3.60 | -- | 0.0044 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
| Bluestar Adisseo Co | 14.95bn | 1.09bn | 30.25bn | 2.73k | 27.76 | 1.91 | -- | 2.02 | 0.4064 | 0.4064 | 5.57 | 5.90 | 0.6887 | 5.18 | 8.01 | 5,466,479.00 | 5.03 | 5.28 | 6.07 | 6.94 | 29.20 | 30.31 | 7.30 | 8.76 | 1.16 | 7.83 | 0.1105 | 21.81 | -9.26 | 2.92 | -95.82 | -43.75 | 2.74 | -19.09 |
Data as of Nov 22 2024. Currency figures normalised to Zhejiang Huahai Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
5.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 16.36m | 1.13% |
| Essence Fund Co., Ltd.as of 30 Jun 2024 | 11.57m | 0.80% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 10.31m | 0.71% |
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 2024 | 9.53m | 0.66% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 6.55m | 0.45% |
| HFT Investment Management Co., Ltd.as of 30 Jun 2024 | 6.28m | 0.43% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2024 | 6.26m | 0.43% |
| CIB Fund Management Co., Ltd.as of 30 Jun 2024 | 5.68m | 0.39% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2024 | 4.85m | 0.33% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 4.42m | 0.30% |
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
